NICE support Bayer’s and Novartis treatments for sight condition

NICE have issued updated guidelines for the treatment of wet age-related macular degeneration, by continuing to back use of both Bayer’s Eylea and Novartis’ Lucentis. According to the guidelines issued by NICE, the intravitreal anti-vascular endothelial growth factor (VEGF) treatment should be recommended for late AMD (wet active) for eyes with visual acuity within a

Continue Reading